Save your Money and Time through Optimized Hit Identification
With exclusive case studies and presentations on cutting-edge hit screening strategies across various target classes, you could have taken the chance to engage in in-depth discussions on tailoring screening approaches to your specific targets. You could have learned from industry leaders and peer experiences & explored how to customize strategies based on your chemical library needs. You could have discovered how to leverage DNA-encoded libraries, high-throughput screening, AI, virtual screening, and fragment-based drug discovery for optimized hit identification and more accurate insights.
What You Missed:
Ensuring the reliability of your hits with PTC Therapeutics by implementing effective triage strategies to identify and correct false positives in your screening assays, optimizing resource use and efficiency
Exploring advanced fragment-based drug discovery techniques with Vanderbilt University, targeting difficult molecules through innovative fragment and structure-based approaches
Collaborating with Bristol Myers Squibb and BPGbio to tackle "undruggable" targets by developing novel drug screening assays for targeted protein degradation (TPD) and molecular glue modalities
Gaining fresh perspectives from Pfizer on the critical role of physiologically relevant cells and assays in structure-activity relationship (SAR) and high-throughput screening (HTS)
Joining Bristol Myers Squibb and St. Jude Children's Research Hospital in exploring the strengths of phenotypic versus target-based screening methods and delving into effective target deconvolution strategies
Who Could You Have Met?
The Hit ID Summit provided the ideal environment for medicinal chemistry, computational chemists & drug discovery experts from both large pharma & biotechs to unite, share experiences & reach conclusions to be applied in hit screening strategies.
Companies on the 2024 Program:
What Attendees from Events in the Series Had to Say:
“Right number of participants, high level of presentations from academy & industry, optimal time dedicated to presentations & networking. Very good organisation.”
GlaxoSmithKline, Structure Based Drug Design Summit
“Great networking opportunities, both reconnecting with old colleagues and meeting other biophysicists for the first time. The small size of the summit helped with this, and made idea exchange/discussion easier.”
Accent Therapeutics, Biophysics for Drug Discovery Summit
“The amalgamation of different approaches to tackle some of the most challenging biophysics problems was a standout for me. 1-1 interactions with different scientists and leaders from different companies was a great opportunity to exchange ideas”
Boehringer Ingelheim, Biophysics for Drug Discovery Summit